CymaBay Therapeutics, Inc. announced new findings from a post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis demonstrating baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31.
